Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Forns

Showing results (201-210 of 298) with videos related to

Pageof 30
Sort By:
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|February 7, 2026
Tecovirimat hepatotoxicity in a man with Mpox infectionDiana Ruiz-Cabrera, Francisco Montoya, Joaquín Sáez-Peñataro, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|February 11, 2005
[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection]Montse Laguno, José María Sánchez-Tapias, Javier Murillas, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 22, 2023
Anticancer drugs are the first cause of drug-induced liver injury in a reference hospitalAnna Pocurull, Maria José Moreta, David Heitman, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 21, 2025
HBcrAg and cirB-RNA Do Not Predict Clinical and Virological Outcomes in Patients With HBeAg-Negative Chronic InfectionSara Battistella, Thais Leonel, Anna Pocurull, et al.
Plos One|October 20, 2012
Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapyStella M Martinez, Juliette Foucher, Jean-Marc Combis, et al.
Journal of Hepatology|April 22, 2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agentXavier Forns, Stuart C Gordon, Eli Zuckerman, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 14, 2025
Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg-Negative Caucasian PatientsAnna Pocurull, Teresa Broquetas, Elena Hoyas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2015
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGEMaria Buti, Stuart C Gordon, Eli Zuckerman, et al.
Journal of Hepatology|June 11, 2018
Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipientsKosh Agarwal, Lluís Castells, Beat Müllhaupt, et al.
Elife|November 3, 2021
Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearanceLouis Shekhtman, Miquel Navasa, Natasha Sansone, et al.
Pageof 30

Showing results (201-210 of 298) with videos related to

Sort By:
Pageof 30
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|February 7, 2026
Tecovirimat hepatotoxicity in a man with Mpox infectionDiana Ruiz-Cabrera, Francisco Montoya, Joaquín Sáez-Peñataro, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|February 11, 2005
[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection]Montse Laguno, José María Sánchez-Tapias, Javier Murillas, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 22, 2023
Anticancer drugs are the first cause of drug-induced liver injury in a reference hospitalAnna Pocurull, Maria José Moreta, David Heitman, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 21, 2025
HBcrAg and cirB-RNA Do Not Predict Clinical and Virological Outcomes in Patients With HBeAg-Negative Chronic InfectionSara Battistella, Thais Leonel, Anna Pocurull, et al.
Plos One|October 20, 2012
Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapyStella M Martinez, Juliette Foucher, Jean-Marc Combis, et al.
Journal of Hepatology|April 22, 2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agentXavier Forns, Stuart C Gordon, Eli Zuckerman, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 14, 2025
Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg-Negative Caucasian PatientsAnna Pocurull, Teresa Broquetas, Elena Hoyas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2015
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGEMaria Buti, Stuart C Gordon, Eli Zuckerman, et al.
Journal of Hepatology|June 11, 2018
Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipientsKosh Agarwal, Lluís Castells, Beat Müllhaupt, et al.
Elife|November 3, 2021
Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearanceLouis Shekhtman, Miquel Navasa, Natasha Sansone, et al.
Pageof 30